ClinicalTrials.gg
TerminatedNCT00624468Updated Feb 17, 2016Results posted

Atacicept in Subjects With Optic Neuritis

A Phase 2 interventional study of Atacicept and Placebo matched to atacicept in Optic Neuritis, sponsored by EMD Serono. Terminated at 28 sites in 11 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\]

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies in Optic Neuritis with a site in United States — 5 open to participants now, 7 under way, 2 of them phase 3. Optic Neuritis · United States.

Enrollment
12th of 20
34 · median 43
Started
2008
the only one that year
Phase 2
4 of 29
2 open now
Registered
7th of 29
by date
Lead sponsor
1 of 29
EMD Serono

Among the 29 studies in Optic Neuritis with a site in United States, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2008, is one of 4 in phase 2, and was the 7th registered.

Optic Neuritis

88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.

Browse Optic Neuritis studies →

Open to participants now

5 of the 29 studies in Optic Neuritis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Optic Neuritis studies recruiting now, 7 (50%) set no upper age limit and 6 (43%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Optic Neuritis with a site in United States, or all of them as a file.
02

Study summary

This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the skin) injections.

03

Conditions studied

  • Optic Neuritis

Keywords

  • atacicept
  • neuritis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of unilateral symptomatic optic neuritis as first clinical manifestation within 28 days between onset of symptoms and study Day 1
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Pre treatment with and immunomodulating drugs
  • Relevant cardiac, hepatic and renal diseases
  • Clinical significant abnormalities in blood cell counts and immunoglobulin levels
  • Clinical significant acute or chronic infections
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Atacicept

    Drug: Atacicept

  • Placebo comparator
    Placebo

    Drug: Placebo matched to atacicept

Interventions

  • DrugTACI receptor-IgG Fc fragment fusion proteinStudies of TACI receptor-IgG Fc fragment fusion proteinTACI receptor-IgG Fc fragment fusion protein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.

  • DrugPlacebo matched to atacicept

    Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV)

    The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and were then averaged over 12 sectors. The change in RNFL thickness at LOV visit was calculated as RNFL thickness at LOV minus RNFL thickness at baseline.

    Time frame: Baseline, LOV (Week 48)

Secondary outcomes

  1. Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye

    The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and was then averaged over 12 sectors. Difference was calculated as RNFL thickness in affected eye minus RNFL thickness in fellow eye.

    Time frame: Weeks 12, 24 and 36

  2. Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24

    The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by OCT measurements and was then averaged over 12 sectors. The change in RNFL thickness at Weeks 12 and 24 was calculated as RNFL thickness at Weeks 12 and 24 minus RNFL thickness at baseline, respectively.

    Time frame: Baseline, Weeks 12 and 24

  3. Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36

    The change in macular thickness at 3 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 3 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 3 mm in the affected eye at baseline, respectively.

    Time frame: Baseline, Weeks 12, 24 and 36

  4. Change From Baseline in Macular Thickness at 6 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36

    The change in macular thickness at 6 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 6 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 6 mm in the affected eye at baseline, respectively.

    Time frame: Baseline, Weeks 12, 24 and 36

  5. Change From Baseline in Macular Volume in the Affected Eye at Weeks 12, 24 and 36

    The change in macular volume in the affected eye at Weeks 12, 24 and 36 was calculated as macular volume in the affected eye at Weeks 12, 24 and 36 minus macular volume in the affected eye at baseline, respectively.

    Time frame: Baseline, Weeks 12, 24 and 36

  6. Low-Contrast Letter Acuity: Total Number of Letters Correctly Identified

    Low-contrast letter acuity was measured by using the Sloan Charts at 1.25 fraction (%) and 2.5%. Sloan letters are a set of optotypes used to test visual acuity. Total number of letters correctly identified in the affected and fellow eye were reported. The possible Sloan Chart range is 0 to 70. More the number of letters identified, better is the visual acuity.

    Time frame: Weeks 12, 24 and 36

  7. Contrast Sensitivity: Total Number of Letters Correctly Identified

    Contrast Sensitivity was measured using the Pelli-Robson Charts. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. Total number of letters correctly identified in the affected and fellow eye were reported. The total possible range is 0 to 48. More the number of letters identified, better is the contrast sensitivity.

    Time frame: Weeks 12, 24 and 36

  8. Contrast Sensitivity: Score Line

    Contrast sensitivity was measured using the Pelli-Robson charts with letters arranged in groups of 3. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. The possible score line range is 0 (visual disability) to 16 (normal contrast sensitivity).

    Time frame: Weeks 12, 24 and 36

  9. Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack

    Conversion to CDMS was defined as experiencing a second clinical attack meeting all of the following criteria: (a) Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both (i) Neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and (ii) Neurological abnormality lasting for at least 24 hours; (b) Absence of fever or known infection (fever with temperature \[axillary, orally or intraauricularly\] greater than 37.5 degree Celsius/99.5 degree Fahrenheit); (c) Objective neurological impairment, correlating with the participant's reported symptoms, defined as either (i) Increase in at least 1 of the functional systems of the Expanded Disability Status Score (EDSS), or (ii) Increase of the total EDSS score. EDSS assesses disability in 8 functional systems and total score ranges from 0 (normal) to 10 (death due to MS). Percentage of participants converting to CDMS (second clinical attack) was reported.

    Time frame: From baseline (Study Day 1) up to Week 36

07

Results

Posted Feb 17, 2016
Limitations and caveats
The Sponsor voluntarily terminated this trial after observing increased Multiple Sclerosis (MS) disease activity in trial 28063 (ATAMS).

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestonePlacebo: Double-blind PeriodAtacicept: Double-blind PeriodPlacebo: SFU PeriodAtacicept: SFU Period
Started171700
Completed3400
Not completed141300
Withdrew: Early termination initiated by sponsor131200
Withdrew: Withdrew prematurely1100
Safety Follow-up (SFU) Period
Participant flow — Safety Follow-up (SFU) Period
MilestonePlacebo: Double-blind PeriodAtacicept: Double-blind PeriodPlacebo: SFU PeriodAtacicept: SFU Period
Started001314
Completed001111
Not completed0023
Withdrew: Lost to follow-up0012
Withdrew: Other0011

Outcome measures

PrimaryChange From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV)

The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and were then averaged over 12 sectors. The change in RNFL thickness at LOV visit was calculated as RNFL thickness at LOV minus RNFL thickness at baseline.

Time frame:
Baseline, LOV (Week 48)
Reported as:
Mean · micrometer
Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV)
micrometerPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Baseline (n = 17, 17)103.893 ± 17.271104.170 ± 8.832
Change at LOV (n = 16, 15)-17.317 ± 15.158-8.636 ± 10.056
SecondaryDifference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye

The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by optical coherence tomography (OCT) measurements and was then averaged over 12 sectors. Difference was calculated as RNFL thickness in affected eye minus RNFL thickness in fellow eye.

Time frame:
Weeks 12, 24 and 36
Reported as:
Mean · micrometer
Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye
micrometerPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Change at Week 12 (n = 13, 13)-14 ± 4-7.9 ± 1.5
Change at Week 24 (n = 4, 5)-7 ± 6.9-10.6 ± 3.7
Change at Week 36 (n = 3, 4)-7.5 ± 8.8-9.4 ± 6.6
SecondaryChange From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24

The RNFL thickness was measured for 12 sectors (every 30 degrees) per eye in triplicate by OCT measurements and was then averaged over 12 sectors. The change in RNFL thickness at Weeks 12 and 24 was calculated as RNFL thickness at Weeks 12 and 24 minus RNFL thickness at baseline, respectively.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · micrometer
Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24
micrometerPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Baseline (n=17, 17)103.893 ± 17.271104.170 ± 8.832
Change at Week 12 (n = 13, 13)-17.036 ± 13.919-9.356 ± 9.532
Change at Week 24 (n = 4, 5)-17.815 ± 16.505-11.234 ± 14.230
SecondaryChange From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36

The change in macular thickness at 3 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 3 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 3 mm in the affected eye at baseline, respectively.

Time frame:
Baseline, Weeks 12, 24 and 36
Reported as:
Mean · micrometer
Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36
micrometerPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Baseline (n = 17, 17)1054.4 ± 76.51070.6 ± 72.7
Change at Week 12 (n = 13, 13)-29.3 ± 34.4-34.0 ± 21.8
Change at Week 24 (n = 4, 5)-72.5 ± 47.0-50.4 ± 47.7
Change at Week 36 (n = 3, 4)-32.7 ± 30.7-40.0 ± 51.3
SecondaryChange From Baseline in Macular Thickness at 6 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36

The change in macular thickness at 6 mm around fovea in the affected eye at Weeks 12, 24 and 36 was calculated as macular thickness at 6 mm in the affected eye at Weeks 12, 24 and 36 minus macular thickness at 6 mm in the affected eye at baseline, respectively.

Time frame:
Baseline, Weeks 12, 24 and 36
Reported as:
Mean · micrometer
Change From Baseline in Macular Thickness at 6 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36
micrometerPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Baseline (n = 17, 17)954.4 ± 57.4947.5 ± 61.3
Change at Week 12 (n = 13, 13)-36.1 ± 28.4-32.8 ± 25.2
Change at Week 24 (n = 4, 5)-63.8 ± 32.7-46.2 ± 36.5
Change at Week 36 (n = 3, 4)-33.3 ± 33.7-34.8 ± 46.0
SecondaryChange From Baseline in Macular Volume in the Affected Eye at Weeks 12, 24 and 36

The change in macular volume in the affected eye at Weeks 12, 24 and 36 was calculated as macular volume in the affected eye at Weeks 12, 24 and 36 minus macular volume in the affected eye at baseline, respectively.

Time frame:
Baseline, Weeks 12, 24 and 36
Reported as:
Mean · cubic micrometer
Change From Baseline in Macular Volume in the Affected Eye at Weeks 12, 24 and 36
cubic micrometerPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Baseline (n = 17, 17)6.8865 ± 0.41996.8794 ± 0.4372
Change at Week 12 (n = 13, 13)-0.2389 ± 0.1991-0.2301 ± 0.1612
Change at Week 24 (n = 4, 5)-0.4630 ± 0.2466-0.3292 ± 0.2674
Change at Week 36 (n = 3, 4)-0.2353 ± 0.2253-0.2533 ± 0.3205
SecondaryLow-Contrast Letter Acuity: Total Number of Letters Correctly Identified

Low-contrast letter acuity was measured by using the Sloan Charts at 1.25 fraction (%) and 2.5%. Sloan letters are a set of optotypes used to test visual acuity. Total number of letters correctly identified in the affected and fellow eye were reported. The possible Sloan Chart range is 0 to 70. More the number of letters identified, better is the visual acuity.

Time frame:
Weeks 12, 24 and 36
Reported as:
Mean · letters
Low-Contrast Letter Acuity: Total Number of Letters Correctly Identified
lettersPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Sloan chart 1.25%, affected eye: Week 12 (n=15,14)14.7 ± 14.715.7 ± 19.0
Sloan chart 1.25%, affected eye: Week 24 (n = 5,5)16.2 ± 13.613.4 ± 18.4
Sloan chart 1.25%, affected eye: Week 36 (n = 3,4)24.7 ± 8.19.8 ± 18.8
Sloan chart 2.5%, affected eye: Week 12 (n=15, 14)25.6 ± 16.722.1 ± 19.5
Sloan chart 2.5%, affected eye: Week 24 (n = 5, 5)26.8 ± 15.221.4 ± 19.3
Sloan chart 2.5%, affected eye: Week 36 (n = 3, 4)38.7 ± 4.720.3 ± 18.7
Sloan chart 1.25%, fellow eye: Week 12 (n=15,14)25.7 ± 13.125.9 ± 16.5
Sloan chart 1.25%, fellow eye: Week 24 (n = 5,5)22.2 ± 16.124.6 ± 18.4
Sloan chart 1.25%, fellow eye: Week 36 (n = 3,4)35.3 ± 4.219.8 ± 20.6
Sloan chart 2.5%, fellow eye: Week 12 (n=15, 14)35.3 ± 13.436.4 ± 12.7
Sloan chart 2.5%, fellow eye: Week 24 (n = 5, 5)33.6 ± 18.235.8 ± 15.4
Sloan chart 2.5%, fellow eye: Week 36 (n = 3, 4)45.7 ± 4.532.5 ± 19.1
SecondaryContrast Sensitivity: Total Number of Letters Correctly Identified

Contrast Sensitivity was measured using the Pelli-Robson Charts. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. Total number of letters correctly identified in the affected and fellow eye were reported. The total possible range is 0 to 48. More the number of letters identified, better is the contrast sensitivity.

Time frame:
Weeks 12, 24 and 36
Reported as:
Mean · letters
Contrast Sensitivity: Total Number of Letters Correctly Identified
lettersPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Affected eye: Week 12 (n = 15, 14)35.4 ± 5.932.4 ± 8.8
Affected eye: Week 24 (n = 5, 5)34.2 ± 6.933.0 ± 4.7
Affected eye: Week 36 (n = 3, 3)37.0 ± 5.334.7 ± 3.2
Fellow eye: Week 12 (n = 15, 14)38.3 ± 4.137.6 ± 3.3
Fellow eye: Week 24 (n = 5, 5)36.2 ± 9.437.4 ± 2.4
Fellow eye: Week 36 (n = 3, 3)39.7 ± 4.040.0 ± 1.0
SecondaryContrast Sensitivity: Score Line

Contrast sensitivity was measured using the Pelli-Robson charts with letters arranged in groups of 3. Pelli-Robson chart is used for clinical measurement of contrast sensitivity and determines the contrast required to read large letters of a fixed size. The possible score line range is 0 (visual disability) to 16 (normal contrast sensitivity).

Time frame:
Weeks 12, 24 and 36
Reported as:
Mean · units on a scale
Contrast Sensitivity: Score Line
units on a scalePlacebo: Double-blind PeriodAtacicept: Double-blind Period
Affected eye: Week 12 (n = 15, 14)12.1 ± 1.510.9 ± 2.9
Affected eye: Week 24 (n = 5, 5)11.4 ± 2.611.2 ± 1.6
Affected eye: Week 36 (n = 3, 3)12.3 ± 2.111.7 ± 1.5
Fellow eye: Week 12 (n = 15, 14)12.9 ± 1.512.7 ± 1.1
Fellow eye: Week 24 (n = 5, 5)11.8 ± 3.312.4 ± 0.5
Fellow eye: Week 36 (n = 3, 3)13.3 ± 1.213.3 ± 0.6
SecondaryPercentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack

Conversion to CDMS was defined as experiencing a second clinical attack meeting all of the following criteria: (a) Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both (i) Neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and (ii) Neurological abnormality lasting for at least 24 hours; (b) Absence of fever or known infection (fever with temperature \[axillary, orally or intraauricularly\] greater than 37.5 degree Celsius/99.5 degree Fahrenheit); (c) Objective neurological impairment, correlating with the participant's reported symptoms, defined as either (i) Increase in at least 1 of the functional systems of the Expanded Disability Status Score (EDSS), or (ii) Increase of the total EDSS score. EDSS assesses disability in 8 functional systems and total score ranges from 0 (normal) to 10 (death due to MS). Percentage of participants converting to CDMS (second clinical attack) was reported.

Time frame:
From baseline (Study Day 1) up to Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack
percentage of participantsPlacebo: Double-blind PeriodAtacicept: Double-blind Period
Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) Second Clinical Attack17.635.3

Adverse events

Collected over Baseline up to Week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Double-blind Period—0/17 (0%)14/17 (82.4%)
Atacicept: Double-blind Period—0/17 (0%)16/17 (94.1%)
Placebo: SFU Period—1/13 (7.7%)6/13 (46.2%)
Atacicept: SFU Period—2/14 (14.3%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo: Double-blind PeriodAtacicept: Double-blind PeriodPlacebo: SFU PeriodAtacicept: SFU Period
MyelitisNervous system disorders0/170/171/130/14
PyrexiaGeneral disorders0/170/171/130/14
BlisterSkin and subcutaneous tissue disorders0/170/171/130/14
Bacterial pyelonephritisInfections and infestations0/170/170/131/14
Multiple sclerosisNervous system disorders0/170/170/131/14
Myelitis transverseNervous system disorders0/170/170/131/14
Most frequent other events
Showing 10 of 109
Most frequent other events
EventPlacebo: Double-blind PeriodAtacicept: Double-blind PeriodPlacebo: SFU PeriodAtacicept: SFU Period
Injection site reactionGeneral disorders3/1711/171/132/14
HeadacheNervous system disorders3/174/170/132/14
DizzinessNervous system disorders4/170/170/131/14
DepressionPsychiatric disorders4/172/170/131/14
Influenza like illnessGeneral disorders0/170/173/132/14
FatigueGeneral disorders3/173/170/130/14
Injection site haematomaGeneral disorders1/173/170/130/14
DiarrhoeaGastrointestinal disorders3/172/170/130/14
CoughRespiratory, thoracic and mediastinal disorders0/171/172/130/14
NasopharyngitisInfections and infestations2/171/170/132/14

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo: Double-blind PeriodAtacicept: Double-blind PeriodTotal
Mean32.3 ± 7.130.6 ± 10.231.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: Double-blind PeriodAtacicept: Double-blind PeriodTotal
Female141327
Male347
08

Study locations

28 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Aurora, Colorado, United States
  • Research Site
    Fairfield, Connecticut, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    East Lansing, Michigan, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Burlington, Vermont, United States
  • Research Site
    Parkville, Victoria, Australia
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Hradec Kralove, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Paris, France
  • Research Site
    Freiburg, Germany
  • Research Site
    Munich, Germany
  • Research Site
    Tübingen, Germany
  • Research Site
    Würzburg, Germany
  • Research Site
    Beyrouth, Lebanon
  • Research Site
    Dbayeh, Lebanon
  • Research Site
    Barcelona, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Lausanne, Switzerland
  • Research Site
    London, United Kingdom
  • Research Site
    Sheffield, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Sep 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2008
First posted
Feb 27, 2008
Start
Jun 2008
Primary completionActual
Sep 2009
CompletionActual
Jan 2011
Results first posted
Feb 17, 2016
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00624468
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Feb 27, 2008
Start date
Jun 2008
Primary completion
Sep 2009
Completion
Jan 2011
Results posted
Feb 17, 2016
Last update
Feb 17, 2016

Study contacts

Medical Responsible
study director · EMD Serono, an affiliate of MerckKGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion